SEMEY, Kazakhstan — A state-of-the-art medical research laboratory is under construction in a suburb of Almaty, Kazakhstan’s business capital, using U.S. funds aimed at helping reorient former biological weapons-related research under the Soviet Union to peaceful public health uses, according to officials involved with the project.
When it opens in 2015, the Central Reference Laboratory is expected to focus on some of the world’s most dangerous emerging pathogens with support from the Nunn-Lugar Cooperative Threat Reduction Program, drawing off of years of U.S. and Kazakhstani joint cooperation.
“We’re going to have here the most up-to-date equipment,” said B.B. Atshabar, director of the Kazakhstan Scientific Center for Quarantine and Zoonotic Diseases, speaking through a translator to a group of U.S. journalists who visited the construction site of the new laboratory on Tuesday.
Once finished, the planned 87,000 square-foot laboratory is slated to be the first of its kind in Central Asia to include research areas that meet internationally recognized Biosafety Level-3 standards, which involve special engineering, design and staff-training protocols intended to minimize the risks of working with potentially deadly disease agents, such as anthrax and plague. Yet more of the lab space, though, will be devoted to Biosafety Level-2 work involving the study of pathogens that pose moderate health hazards.
“The ultimate goal of the laboratory will be its international accreditation,” Atshabar said. “The results that will be achieved in this laboratory will be open to all of the world” to utilize, he said.
The focus of work at the future facility will be on developing improved diagnostic tools and countermeasures for pathogens that affect both humans and animals. The laboratory is also expected to aid neighboring Central Asian states in diagnosing and controlling the spread of new disease strains, he said.
Anthrax and plague are endemic to Kazakhstan and have been public health concerns here for some time. Kazakhstani scientists have developed considerable expertise into these pathogens but their research up until now has taken place in local laboratories that lack the internationally recognized BSL-3 standards, according to Atshabar.
Under the Soviet Union, “there wasn’t really a notion of peer-reviewed science or transparency at all. Most of what they did was very tightly classified and they had a lot of overlap with the military,” said Phil Starling, the program director for science engagement at CRDF Global, a nonprofit that works on Cooperative Threat Reduction programs in Kazakhstan and elsewhere under contract with the U.S. government. Standard practice at that time was for scientists in Kazakhstan identifying new strains of plague, for example, to send samples back to Moscow where they would be examined and studied specifically for potential application as biological weapons, he said.
Kazakhstan became an independent nation in December 1991, following the dissolution of the Soviet Union.
Through the CTR program, the United States has worked to steer Kazakhstani scientists with a background in diseases such as plague and anthrax to nonmilitary research that is transparent and published under the principles of global science, said Starling. He was interviewed by phone in the United States late last month.
“A big part of the reorientation was introducing [Kazakhstani scientists] to the principles of western [global] science,” he said. “You get funding based on the rigor of your research and the validity of your research, not necessarily other political priorities,” he said.
Another aspect of CTR work in Kazakhstan is finding employment for those scientists with backgrounds in biological-weapon related research, so that they will not be tempted to sell their expertise to terrorists or rogue nations.
“We’ve done our best to employ these people who have this knowledge. It’s one of these challenges that you cannot erase this knowledge from someone’s mind,” said Lt. Col. Charles Carlton, director of the U.S. Defense Threat Reduction Office in Kazakhstan.
“I do think that through our efforts, through U.S. funding, Kazakhstani funding, we are doing our best to employ these people,” he said on Tuesday to reporters on a trip organized by the International Reporting Project.
Funding for the $100 million construction of the Central Reference Laboratory is coming entirely from the United States. Once it is up and running, Washington each year will gradually reduce the amount of funds it provides to Kazakhstan to operate the scientific facility, until the government in Astana is fully underwriting the laboratory, Carlton said.
The CRL facility will contain 5,400 square feet of BSL-3 research space, according to Dan Erbach, the site construction manager for AECOM, the company building the facility.
The U.S. government is also providing approximately $5.6 million to build a separate site featuring BSL-3 laboratory space in the village of Otar in Kazakhstan’s Zhambylskaya region. The facility is intended to provide an early warning of any new disease outbreaks that occur in the region and is intended to complement rather than duplicate the work done at the Central Reference Laboratory in Almaty, Carlton said. The Otar facility is expected to be completed next April.
What We're Following See More »
Foreign Policy takes a look at the future of mining the estimated "100,000 near-Earth objects—including asteroids and comets—in the neighborhood of our planet. Some of these NEOs, as they’re called, are small. Others are substantial and potentially packed full of water and various important minerals, such as nickel, cobalt, and iron. One day, advocates believe, those objects will be tapped by variations on the equipment used in the coal mines of Kentucky or in the diamond mines of Africa. And for immense gain: According to industry experts, the contents of a single asteroid could be worth trillions of dollars." But the technology to get us there is only the first step. Experts say "a multinational body might emerge" to manage rights to NEOs, as well as a body of law, including an international court.
Not to be outdone by Jeffrey Goldberg's recent piece in The Atlantic about President Obama's foreign policy, the New York Times Magazine checks in with a longread on the president's economic legacy. In it, Obama is cognizant that the economic reality--73 straight months of growth--isn't matched by public perceptions. Some of that, he says, is due to a constant drumbeat from the right that "that denies any progress." But he also accepts some blame himself. “I mean, the truth of the matter is that if we had been able to more effectively communicate all the steps we had taken to the swing voter,” he said, “then we might have maintained a majority in the House or the Senate.”
Ronald Reagan's children and political allies took to the media and Twitter this week to chide funnyman Will Ferrell for his plans to play a dementia-addled Reagan in his second term in a new comedy entitled Reagan. In an open letter, Reagan's daughter Patti Davis tells Ferrell, who's also a producer on the movie, “Perhaps for your comedy you would like to visit some dementia facilities. I have—I didn’t find anything comedic there, and my hope would be that if you’re a decent human being, you wouldn’t either.” Michael Reagan, the president's son, tweeted, "What an Outrag....Alzheimers is not joke...It kills..You should be ashamed all of you." And former Rep. Joe Walsh called it an example of "Hollywood taking a shot at conservatives again."
In a sign that she’s ready to put a longer-than-expected primary battle behind her, former Secretary of State Hillary Clinton (D) is no longer going on the air in upcoming primary states. “Team Clinton hasn’t spent a single cent in … California, Indiana, Kentucky, Oregon and West Virginia, while” Sen. Bernie Sanders’ (I-VT) “campaign has spent a little more than $1 million in those same states.” Meanwhile, Sen. Jeff Merkley (D-OR), Sanders’ "lone backer in the Senate, said the candidate should end his presidential campaign if he’s losing to Hillary Clinton after the primary season concludes in June, breaking sharply with the candidate who is vowing to take his insurgent bid to the party convention in Philadelphia.”
The team behind the bestselling "Clinton Cash"—author Peter Schweizer and Breitbart's Stephen Bannon—is turning the book into a movie that will have its U.S. premiere just before the Democratic National Convention this summer. The film will get its global debut "next month in Cannes, France, during the Cannes Film Festival. (The movie is not a part of the festival, but will be shown at a screening arranged for distributors)." Bloomberg has a trailer up, pointing out that it's "less Ken Burns than Jerry Bruckheimer, featuring blood-drenched money, radical madrassas, and ominous footage of the Clintons."